Oral vinorelbine in the treatment of non-small-cell lung cancer-Reference-Cited by-同舟云学术

Oral vinorelbine in the treatment of non-small-cell lung cancer

Published:2014-06-27 Issue:11 Volume:15 Page:1585-1599
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Barletta Giulia,Genova Carlo,Rijavec Erika,Burrafato Giovanni,Biello Federica,Sini Claudio,Dal Bello Maria Giovanna,Coco Simona,Truini Anna,Vanni Irene,Alama Angela,Beltramini Sabrina,Grassi Maria Attilia,Boccardo Francesco,Grossi Francesco

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/14656566.2014.934224

Reference54 articles.

1. Cancer statistics, 2014

2. Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

3. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules

4. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine

5. Vinorelbine in Cancer Therapy

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vinorelbine causes a neuropathic pain-like state in mice via STING and MNK1 signaling associated with type I interferon induction;iScience;2024-02

2. Vinorelbine causes a neuropathic pain-like state in mice via STING and MNK1 signaling associated with type I interferon induction;2023-06-05

3. Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer—a valid option for cisplatin-unfit patients?;Strahlentherapie und Onkologie;2021-08-19

4. Metronomic oral vinorelbine doublet chemotherapy with carboplatin in treatment of advanced lung cancer: a feasibility and safety study;F1000Research;2021-07-28

5. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03);Therapeutic Advances in Medical Oncology;2021-01